Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Adaptimmune Therapeutics Plc

ADAP
Current price
0.62 USD -0.0071 USD (-1.13%)
Last closed 0.66 USD
ISIN US00653A1079
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 185 054 592 USD
Yield for 12 month +23.96 %
1Y
3Y
5Y
10Y
15Y
ADAP
21.11.2021 - 28.11.2021

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Address: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

2.27 USD

P/E ratio

Dividend Yield

Current Year

+60 281 000 USD

Last Year

+27 148 000 USD

Current Quarter

+40 901 000 USD

Last Quarter

+128 231 000 USD

Current Year

+50 423 941 USD

Last Year

-100 578 000 USD

Current Quarter

+40 901 000 USD

Last Quarter

+125 629 679 USD

Key Figures ADAP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -72 880 000 USD
Operating Margin TTM 53.58 %
PE Ratio
Return On Assets TTM -15.84 %
PEG Ratio 0.11
Return On Equity TTM -65.04 %
Wall Street Target Price 2.27 USD
Revenue TTM 141 459 008 USD
Book Value 0.17 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 2399.6 %
Dividend Yield
Gross Profit TTM -100 578 000 USD
Earnings per share -0.17 USD
Diluted Eps TTM -0.17 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin -51.25 %

Dividend Analytics ADAP

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ADAP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date 30.03.2018

Stock Valuation ADAP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.4197
Price Sales TTM 1.3082
Enterprise Value EBITDA -1.7076
Price Book MRQ 2.3135

Financials ADAP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ADAP

For 52 weeks

0.43 USD 2.05 USD
50 Day MA 0.81 USD
Shares Short Prior Month 5 349 350
200 Day MA 1.1 USD
Short Ratio 4.71
Shares Short 6 906 004
Short Percent 3.14 %